Norepinephrine vs Phenylephrine During General Anesthesia

• Status: Recruiting
• Trial end date: 2022-05-01
• Target enrollment: 0
• Participant gender: All

Summary

50 million patients undergo surgery each year in the United States. Postoperative mortality is considered the third leading cause of death worldwide. Hypotension during surgery have been linked to increased postoperative morbidity and mortality. Episodes of hypotension during surgery are associated with an increased risk of acute kidney injury, stroke, cardiac events and death. Treating or preventing hypotension during general anesthesia and major surgery was found to improve outcomes. At this time, it is unclear what is the best vasopressor to maintain blood pressure during surgery under general anesthesia. With this pilot pragmatic trial, the investigators will explore the impact of norepinephrine (NE) or phenylephrine (PE) on post-operative events in patients undergoing major surgery with general anesthesia and needing vasopressors infusion to maintain their systemic arterial pressure.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of California, San Francisco
• Treatments: Norepinephrine; Oxymetazoline; Phenylephrine

Criteria

Inclusion Criteria:

• age 18 Years and older

• Surgery under general anesthesia and requiring infusion of vasopressors to maintain the mean arterial pressure.

• Surgery duration>2 hours

Exclusion Criteria:

• Cardiac surgery

• Patients on ECMO

• Organ transplantation

• Outpatient (come-and-go surgery)

• Obstetric procedures

• Patient already receiving NE or PE before induction of anesthesia

• Patients transferred immediately (i.e. within 24 hours) after surgery to another hospital.

• Patients with severe trauma